Real-World Effects of Mirabegron in Patients with Chronic Neurogenic Detrusor Overactivity – A Retrospective Cohort Study

Real-World Effects of Mirabegron in Patients with Chronic Neurogenic Detrusor Overactivity – A Retrospective Cohort Study

Jörg Krebs,1 Jürgen Pannek,2,3 Franziska Rademacher,2 Jens Wöllner2 1Clinical Trial Unit, Swiss Paraplegic Centre, Nottwil, Switzerland; 2Neuro-Urology, Swiss Paraplegic Centre, Nottwil, Switzerland; 3Department of Urology, Inselspital, Bern University Hospital, University...

Full description

Bibliographic Details
Main Authors:	Krebs J, Pannek J, Rademacher F, Wöllner J
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-05-01
Series:	Research and Reports in Urology
Subjects:	spinal cord injury detrusor overactivity neurogenic lower urinary tract dysfunction antimuscarinics onabotulinum toxin
Online Access:	https://www.dovepress.com/real-world-effects-of-mirabegron-in-patients-with-chronic-neurogenic-d-peer-reviewed-article-RRU

Similar Items

Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity
by: Sheng-Fu Chen, et al.
Published: (2015-07-01)

The use of botulinum toxin for the treatment of overactive bladder syndrome
by: Bogdan Orasanu, et al.
Published: (2013-01-01)

Clinical outcomes of botulinum toxin A management for neurogenic detrusor overactivity: meta-analysis
by: Shang-Jun Wu, et al.
Published: (2019-01-01)

In Patients with Neurogenic Detrusor Overactivity and Hinman’s Syndrome: Would Intravesical Botox Injections Decrease the Incidence of Symptomatic Urinary Tract Infections
by: Banakhar M, et al.
Published: (2021-09-01)

Taiwanese Continence Society clinical guidelines for diagnosis and management of neurogenic lower urinary tract dysfunction
by: Hann-Chorng Kuo, et al.
Published: (2014-06-01)

Efficacy and Safety of OnabotulinumtoxinA in Patients With Neurogenic Detrusor Overactivity Caused by Spinal Cord Injury: A Systematic Review and Meta-analysis
by: Guang-Ping Li, et al.
Published: (2018-12-01)

ONABOTULINUM TOXIN-A FOR OVERACTIVE BLADDER
by: Mahmood Shakir Abdulkarim
Published: (2016-12-01)

Urodynamic Detrusor Overactivity in Patients with Overactive Bladder Symptoms
by: Mohammed A. Al-Ghazo, et al.
Published: (2011-03-01)

Efficacy and safety of tolterodine in subjects with symptoms of overactive bladder: An open label, noncomparative, prospective, multicentric study
by: Anant Kumar
Published: (2002-01-01)

Predicting Refractory Detrusor Overactivity: Are There any Clues at Diagnosis
by: Kylie J Mansfield, et al.
Published: (2013-12-01)

Use of onabotulinum toxin A in patients with idiopathic overactive bladder and a lack of efficacy, intolerance or contraindication with anticholinergics
by: Irma Amparo Ospina-Galeano, et al.
Published: (2018-01-01)

Management of urinary tract infections in patients with neurogenic bladder: challenges and solutions
by: Pannek J, et al.
Published: (2017-07-01)

Efficacy and Safety of OnabotulinumtoxinA in Treating Neurogenic Detrusor Overactivity: A Systematic Review and Meta-analysis
by: Xin Zhou, et al.
Published: (2015-01-01)

Detrusor Overactivity May Be a Prognostic Factor for Better Response to Combination Therapy Over Monotherapy in Male Patients With Benign Prostatic Enlargement and Storage Lower Urinary Tract Symptoms
by: Vasileios Sakalis, et al.
Published: (2021-03-01)

Impact of urinary incontinence on health-related quality of life, daily activities, and healthcare resource utilization in patients with neurogenic detrusor overactivity
by: Tang, Derek, et al.
Published: (2014)

The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment
by: Eric Chieh-Lung Chou, et al.
Published: (2014-08-01)

Efficacy and Adverse Events Associated With Use of OnabotulinumtoxinA for Treatment of Neurogenic Detrusor Overactivity: A Meta-Analysis
by: Hejia Yuan, et al.
Published: (2017-03-01)

Outcomes of Intradetrusor Onabotulinum Toxin A Therapy in Overactive Bladder Refractory to Sacral Neuromodulation
by: Hamilton Trinh, et al.
Published: (2019-09-01)

Managing Urological Disorders in Multiple Sclerosis Patients: A Review of Available and Emerging Therapies
by: Riccardo Bientinesi, et al.
Published: (2020-06-01)

Does Reduction of Number of Intradetrusor Injection Sites of aboBoNTA (Dysport®) Impact Efficacy and Safety in a Rat Model of Neurogenic Detrusor Overactivity?
by: Amélie Huynh Le Maux, et al.
Published: (2015-12-01)

Stroke and lower urinary tract symptoms: A neurosurgical view
by: Yu-Cheng Chou, et al.
Published: (2019-01-01)

Meta-Analysis of Randomized Controlled Trials Using Botulinum Toxin A at Different Dosages for Urinary Incontinence in Patients With Overactive Bladder
by: Qin-Qin Gong, et al.
Published: (2020-01-01)

Prediction of autonomic dysreflexia during urodynamics: a prospective cohort study
by: Matthias Walter, et al.
Published: (2018-04-01)

Botulinum Toxin in Neurogenic Detrusor Overactivity
by: Carlos Arturo Levi D'Ancona, et al.
Published: (2012-09-01)

Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury?
by: Sheng-Fu Chen, et al.
Published: (2021-01-01)

Sphingosine Kinase 1 urothelial expression is increased in patients with neurogenic detrusor overactivity
by: Quentin Ballouhey, et al.
Published: (2015-12-01)

Clinical usefulness of urine cytology in the detection of bladder tumors in patients with neurogenic lower urinary tract dysfunction
by: Pannek J, et al.
Published: (2017-12-01)

Time-Related Changes in Detrusor Overactivity in Awake Rats with Spinal Cord Injury Observed by Simultaneous Registrations of Intravesical and Intraabdominal Pressures
by: Long-Hu Jin, et al.
Published: (2011-03-01)

A retrospective study of treatment persistence and adherence to mirabegron versus antimuscarinics, for the treatment of overactive bladder in Spain
by: Jameel Nazir, et al.
Published: (2018-09-01)

Effect of Memantine on Overactive Detrusor in Rats With Spinal Cord Injury
by: Cüneyd Özkürkçügil, et al.
Published: (2010-05-01)

Prevalence and urodynamic characteristics of detrusor overactivity with impaired contractility in the community-dwelling elderly with non-neurogenic lower urinary tract symptoms: Is it from a single or two independent bladder dysfunctions?
by: Seong Jin Jeong, et al.
Published: (2021-07-01)

Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity
by: Cristiano M. Gomes, et al.
Published: (2010-02-01)

Additional low-dose antimuscarinics can improve overactive bladder symptoms in patients with suboptimal response to beta 3 agonist monotherapy
by: Jung Hyun Shin, et al.
Published: (2017-07-01)

A Korean Postmarketing Study Assessing the Effectiveness of OnabotulinumtoxinA for the Treatment of Neurogenic Detrusor Overactivity or Idiopathic Overactive Bladder Using a Validated Patient-Reported Outcome Measure
by: Kwang Jin Ko, et al.
Published: (2019-03-01)

Long-term response of different Botulinum toxins in refractory neurogenic detrusor overactivity due to spinal cord injury
by: Giuseppe Lombardi, et al.

Botulinum toxin A for the Treatment of Overactive Bladder
by: Po-Fan Hsieh, et al.
Published: (2016-02-01)

Patient treatment preferences for symptomatic refractory urodynamic idiopathic detrusor overactivity
by: Christina L Fontaine, et al.
Published: (2017-01-01)

Definition and symptoms of underactive bladder
by: Alan D. Uren, et al.
Published: (2017-12-01)

Insights into the Management of Overactive Bladder: What Difference Can Mirabegron Make?
by: Ömer Acar, et al.
Published: (2019-06-01)

A Urodynamic Comparison of Neural Targets for Transcutaneous Electrical Stimulation to Acutely Suppress Detrusor Contractions Following Spinal Cord Injury
by: Sean Doherty, et al.
Published: (2019-12-01)